Digestery
Longevity supplements › NMN and Aging › Studies

Randomized trial · measured lab tests or safety

A 10-week trial of NMN in women with prediabetes found better muscle insulin response

Yoshino and colleagues · Science (New York, N.Y.) · 2021

Original title: Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women.

Under review. A person has not yet checked this summary against the paper. It is written from the PubMed abstract. Until a person checks it, search engines are asked not to list this page.

What the study found

Points to benefit

Muscle response to insulin and muscle insulin signaling rose after NMN but not after placebo. Muscle remodeling genes were turned up.

The study at a glance

Type of study
Randomized trial
Who or what was studied
Postmenopausal women with prediabetes who were overweight or obese
What was tested
NMN vs placebo for 10 weeks
What it measured
Lab tests or markers
How long
10 weeks
Trial registration
NCT03151239
Who has a stake
Company stake
Authors receive patent-licensing fees tied to NMN, hold an NMN patent application, and one has Janssen and Merck ties.
Journal
Science (New York, N.Y.), 2021
Source
PubMed record 33888596. This page is based on the abstract only.

How much this study counts

  • ✓Randomized: people were put into groups by chance, so the groups start out alike.
  • ✓Compared with a placebo, a dummy treatment.
  • •The abstract does not say how many people took part.
  • –Short: 10 weeks. Longer-term effects are unknown.
  • –Measured lab tests or markers, which stand in for aging and age-related decline. A better marker does not always mean better health.
  • –Company stake: Authors receive patent-licensing fees tied to NMN, hold an NMN patent application, and one has Janssen and Merck ties.
  • •Summarized from the PubMed abstract only. The full paper may hold details the abstract leaves out.

✓ Strength– Limit• Note

These points come from fixed rules about the type of study, its size and length, what it measured, and who has a stake. Every study on Digestery gets the same rules.

Where this study sits

Each dot is one on-topic paper on this question. Steps near the top answer the question more directly.

↑ Stronger evidence

  1. Trials in people: aging and age-related decline

    0

    Not done yet. This is the step that would answer the question.

  2. Trials in people: other measures

    9

    3 benefit, 2 mixed, 4 no difference

  3. Trials in people: lab tests or safety

    7

    4 benefit, 1 mixed, 2 no difference

    ↑ This study is the ringed dot

  4. Population studies

    0

    None among the papers we read.

  5. Blood levels and genes

    0

    None among the papers we read.

  6. Animals

    6

    5 benefit, 1 mixed

↓ Weaker evidence

  • Points to benefit
  • Mixed
  • No difference
  • No direction
  • Points to harm

How it fits with the other research

The short answer to “Does NMN slow aging?”

Not shown in people so far.

Confidence: very low. Based on 29 on-topic papers.

Read the full answer

Of the other 6 papers on the same step: 3 benefit, 1 mixed, 2 no difference. This one found benefit.

Other papers on the same step

See all 29 studies on this question

How this page was made

Label

First read of the abstract
Claude Sonnet
Independent second read
Claude Haiku
Differences settled
The reviewer corrected 1 field after reading the abstract. Claude Opus 5.5.
Headline
Claude Sonnet, from the checked study record. A script checked its numbers and wording.
Numbers
Checked against the abstract by a script
“How much this study counts”
Fixed rules, the same for every study
Source check by a person
Not yet. Required before search engines may list this page.

Spot an error? Email a flag with a link to your source, or use the form on the question page.